- Home
- Medical news & Guidelines
- Anesthesiology
- Cardiology and CTVS
- Critical Care
- Dentistry
- Dermatology
- Diabetes and Endocrinology
- ENT
- Gastroenterology
- Medicine
- Nephrology
- Neurology
- Obstretics-Gynaecology
- Oncology
- Ophthalmology
- Orthopaedics
- Pediatrics-Neonatology
- Psychiatry
- Pulmonology
- Radiology
- Surgery
- Urology
- Laboratory Medicine
- Diet
- Nursing
- Paramedical
- Physiotherapy
- Health news
- Fact Check
- Bone Health Fact Check
- Brain Health Fact Check
- Cancer Related Fact Check
- Child Care Fact Check
- Dental and oral health fact check
- Diabetes and metabolic health fact check
- Diet and Nutrition Fact Check
- Eye and ENT Care Fact Check
- Fitness fact check
- Gut health fact check
- Heart health fact check
- Kidney health fact check
- Medical education fact check
- Men's health fact check
- Respiratory fact check
- Skin and hair care fact check
- Vaccine and Immunization fact check
- Women's health fact check
- AYUSH
- State News
- Andaman and Nicobar Islands
- Andhra Pradesh
- Arunachal Pradesh
- Assam
- Bihar
- Chandigarh
- Chattisgarh
- Dadra and Nagar Haveli
- Daman and Diu
- Delhi
- Goa
- Gujarat
- Haryana
- Himachal Pradesh
- Jammu & Kashmir
- Jharkhand
- Karnataka
- Kerala
- Ladakh
- Lakshadweep
- Madhya Pradesh
- Maharashtra
- Manipur
- Meghalaya
- Mizoram
- Nagaland
- Odisha
- Puducherry
- Punjab
- Rajasthan
- Sikkim
- Tamil Nadu
- Telangana
- Tripura
- Uttar Pradesh
- Uttrakhand
- West Bengal
- Medical Education
- Industry
Bayer Takes Roundup Cancer Case Back to Supreme Court

Bayer has warned U.S. lawmakers it might halt Roundup sales to farmers, unless they can strengthen legal protection against the litigation.
Delhi: Bayer said on Friday it was again petitioning the U.S. Supreme Court to sharply limit legal claims that its Roundup weedkiller causes cancer, seeking to avoid potentially billions of dollars in damages.
Bayer said in its petition that consumers should not be able to sue it under state law for failing to warn that Roundup increases cancer risk because the U.S. Environmental Protection Agency has found no such risk and requires no such warning. In fact, it argued, federal law does not allow it to add any warning to the product beyond the EPA-approved label.
The company tried to make that case to the Supreme Court and was rebuffed in 2022, but a federal appeals court has since agreed with the company in a split from other appeals courts. The Supreme Court is generally more likely to take cases where federal appeals courts are divided.
A Supreme Court victory for Bayer would likely make it much more difficult for the lawsuits to continue, though it is not clear whether it would eliminate them entirely.
Friday's petition came in the case of John Durnell, who in 2023 won a $1.25-million verdict in a St. Louis, Missouri state court. Bayer has been hit with much larger verdicts over Roundup, most recently a $2.1-billion award last month to a plaintiff in Georgia.
The company has paid about $10 billion to settle claims that Roundup, based on the herbicide glyphosate, causes cancer. About 67,000 further cases are pending, for which the group has set aside $5.9 billion in legal provisions.
CEO Bill Anderson has struggled to revive a share price that has plunged by more than 70% since Bayer's $63-billion acquisition of Monsanto in 2018 that saddled it with costly litigation and debt.
The company's problems include the glyphosate litigation, a 2023 development setback for its most promising experimental medicine, weak agriculture markets and pressure from some investors to separate or sell businesses.
Bayer plans to seek shareholder approval to raise equity capital worth close to 35% of its outstanding shares over the next three years to cover possible costs of U.S. litigation.
The company has warned U.S. lawmakers it could stop selling Roundup, which is widely used by U.S. farmers, unless they can strengthen legal protection against the litigation. It has already replaced glyphosate with other ingredients in the home consumer version of Roundup.
Farhat Nasim joined Medical Dialogue an Editor for the Business Section in 2017. She Covers all the updates in the Pharmaceutical field, Policy, Insurance, Business Healthcare, Medical News, Health News, Pharma News, Healthcare and Investment. She is a graduate of St.Xavier’s College Ranchi. She can be contacted at editorial@medicaldialogues.in Contact no. 011-43720751
Next Story